Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Rorer's Nasacort AQ Nasal Spray

This article was originally published in The Tan Sheet

Executive Summary

Rorer's Nasacort AQ Nasal Spray: Rhone-Poulenc Rorer submits sNDA for approval of product's benefits to "children as young as four," RPR announced Oct. 22. Submission contains results from two double-blind, placebo-controlled trials involving 538 children with seasonal or perennial allergic rhinitis. At doses of 110 mcg or 220 mcg once daily, Nasacort AQ was found to effect "statistically significant reductions of allergic rhinitis symptoms." Pharyngitis, fever, rhinitis, and flu symptoms were the most commonly reported adverse events. Should Nasacort switch to OTC, Ciba would gain rights to its marketing per the companies' December 1994 agreement ("The Tan Sheet" Jan. 2, 1995, p. 4)...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts